Navigation Links
Niche in Medical Technology

ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease

... and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information ... and cornea's dry eye damage and ISTA's expectation of becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except ...

ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium

... and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information ... approval of ecabet sodium and ISTA's expectation of becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except ...

ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration

... and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information ... within ten months of filing and ISTA's expectation of becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except ...

ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%

... every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information ... a new product to market every 12 to 18 months and becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except ...

ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing

... every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information ... NDA with the FDA in the second half of 2008, and becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except ...

ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation

... every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information ... a new product to market every 12 to 18 months, and becoming the leading niche ophthalmic pharmaceutical company are forward- looking statements. Except ...

ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting

... every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information ... a new product to market every 12 to 18 months and becoming the leading niche ophthalmic pharmaceutical company in the U.S., are forward-looking ...

ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting

... products and is developing a strong product pipeline to fuel future growth and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at ...

Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting

... inhibitor of CK2 and modulates key survival pathways in cancer cells. CX-4945, which has broad therapeutic potential in common cancers as well as in niche indications, has advanced rapidly into Phase I clinical trials. The oral symposium will address the identification of pathway-specific ...

Savient Provides Update on Pegloticase BLA

... Inc. is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, KRYSTEXXA (TM) (pegloticase) for treatment-failure gout, has reported positive ...

Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients

... Inc. is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The Company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 ...

Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)

... Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com . Forward-Looking Statements This release contains ...

Insmed CEO to Present at Congressional Briefing on Follow-On Biologics

... Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com . Forward-Looking Statements This release contains ...

Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company

... Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com . The Follow-on Biologics Market According to ...

Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger, and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs

... Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com . Forward-Looking Statements This release contains ...

Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

... development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at ...

Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)

... Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com . Forward-Looking Statements This release contains ...

Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market

... is one of the fastest growing biopharmaceutical companies in India. As an independent biopharmaceutical company of the INTAS Group, it has carved a niche in the biotechnology sector in the country. The company has fully integrated biopharmaceutical operations with an ultra modern R&D facility and an EU ...

Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger, and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)

... development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at ...

Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics

... Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. Insmed has a state-of-the-art, FDA-approved biologic commercial manufacturing facility in Boulder, Colorado and a ...

Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis

... Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com . Forward-Looking Statements This release contains ...

Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy

... Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com . Forward-Looking Statements This release contains ...

Replidyne Provides Strategic Update

... has suspended the development of topical antibiotic REP8839 due to the additional investment required to optimize the formulation and the niche market opportunity. -- Development strategy for faropenem. Replidyne will continue its ongoing placebo-controlled Phase III trial for faropenem ...

Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...

PositiveFriends.com Launches STD Social Networking Site Balancing Dating with Online Support Features

... by HPV. With one-third of all single and dating Americans now exploring online personal ads (BusinessWeek, 2006), the market for specialized, niche dating and social services has never been hotter. "It was important we position the dating service in the context of a socially responsible ...

New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG

... areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with ...
Other Contents
(Date:8/29/2014)... made some surprising discoveries about the body,s initial ... (SIV), the team found that specialized cells in ... to viral invasion and are the source of ... beta (IL-1β). , Though aimed at the ... gut epithelium that provides a barrier to protect ...
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and ... the UT Health Science Center at San Antonio, have ... the longest-lived rodent, the naked mole rat. , ... naked mole rats protects and alters the activity of ... proteins. , The factor also protects proteasome function in ...
(Date:8/29/2014)... about what genetic changes transform wild animals into domesticated ... is a University of Montana assistant professor, has made ... of the brain and the nervous system were particularly ... 28 in Science and gives answers to ... ., The domestication of animals and plants, a prerequisite ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
(Date:8/31/2014)... Obese youths have a nearly six fold risk ... ,22 000 young people from the PEP Family ... Professor Peter Schwandt from Germany. , Professor Schwandt ... children and adolescents is continuing to rise in ... considered a driving force for cardiovascular disease, we ...
(Date:8/31/2014)... California (PRWEB) August 31, 2014 ... environmentally harmful disc brake dust at the source ... , Problem: Millions of vehicles globally emit brake ... ingredients in the friction materials (disc brake pads) ... the nations’ water systems. For example, copper impairs ...
(Date:8/31/2014)... 2014 Priya Khan, Director of ... concern over misinformation about weight-loss supplements saying, “Consumers ... often, misleading information being propagated by unscrupulous companies ... are weighing in on the subject. , NutriGold’s ... and especially weight-loss products and to provide them ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 To make ... supplement brand they can trust, NutriGold is shipping complimentary ... A form has been set up to make taking ... , According to Priya Khan, Director of Research ... customers purchase one of our products, they are entrusting ...
(Date:8/31/2014)... 2014 “Prohibition is our history,” ... our future: the present ~ that’s political.” , ... , new on the Bryan William Brickner Blog, ... system (CS) modulation and homeostasis - including one ... use. The Publius CS update includes: heteromerization ...
Breaking Medicine News(10 mins):Health News:Obese youths have a nearly 6 fold risk of hypertension 2Health News:CBPModular Technology with Global Patent Coverage Solves Vehicle Wheel Brake Dust Problem 2Health News:New Reasons to Verify Label Claims on Weight-loss Products Before Buying 2Health News:New Reasons to Verify Label Claims on Weight-loss Products Before Buying 3Health News:Whole-food Supplement Samples Now Offered by NutriGold 2Health News:Whole-food Supplement Samples Now Offered by NutriGold 3Health News:Homeostasis: Publius’ Alcohol Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2
Other TagsOther Tags